Best Monjuvi (Tafasitamab) Medicine in India

Monjuvi (Tafasitamab) is a targeted anticancer medicine used in combination with lenalidomide, followed by Monjuvi alone, to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation. It is a monoclonal antibody that targets the CD19 protein found on B-cells, helping the immune system recognize and destroy abnormal lymphoma cells.

Monjuvi (Tafasitamab) is administered by a healthcare professional through an intravenous infusion. It is given according to a specific treatment schedule, initially in combination with lenalidomide and later as Monjuvi alone, as prescribed by your doctor. Patients are monitored during and after infusions for possible infusion-related reactions. Regular blood tests may be required to monitor blood cell counts and overall health.

Common side effects of Monjuvi may include fatigue, fever, diarrhea, cough, respiratory infections, swelling, nausea, and low blood cell counts. Serious side effects such as infections, infusion-related reactions, and low blood cell counts may also occur. Inform your doctor promptly if you develop fever, chills, difficulty breathing, severe weakness, unusual bleeding, or other concerning symptoms. Before starting treatment, tell your doctor about your medical conditions and all medicines, vitamins, herbal products, and supplements you are taking.

Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Monjuvi (Tafasitamab) is used in combination with lenalidomide, followed by Monjuvi alone, to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation. It targets the CD19 protein on B-cells and helps the immune system recognize and destroy abnormal lymphoma cells, helping to reduce cancer cell growth and control disease progression.

Some side effects of Monjuvi (Tafasitamab) may improve as your body adjusts to the medicine. Consult your doctor if any side effect persists, becomes severe, or causes concern.

Common Side Effects of Monjuvi (Tafasitamab)

Monjuvi (Tafasitamab) is administered by a healthcare professional through an intravenous infusion. It is initially given in combination with lenalidomide according to a specific treatment schedule prescribed by your doctor, followed by Monjuvi alone. The infusion rate may be adjusted based on how you tolerate the treatment. Regular blood tests and medical check-ups may be required to monitor blood cell counts and treatment response.

Monjuvi is a targeted monoclonal antibody that binds to the CD19 protein found on B-cells, including abnormal lymphoma cells. After attaching to CD19, it helps activate the body's immune system to recognize and destroy these cancer cells. This reduces abnormal B-cell growth and helps control relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

• Keep the unopened vial refrigerated at 2°C to 8°C.
• Do not expose the vial to freezing temperatures, and retain it in the original carton for light protection.
• After dilution, use the infusion solution within 24 hours when refrigerated at 2°C to 8°C or within 12 hours when kept at room temperature.
• Store the medicine securely in a place that is inaccessible to children.

Alcohol CONSULT YOUR DOCTOR

Consult your doctor before consuming alcohol during treatment with Monjuvi (Tafasitamab).

Pregnancy CONSULT YOUR DOCTOR

Monjuvi is used with lenalidomide, which can cause serious birth defects. Women who can become pregnant must follow the required pregnancy-prevention measures and use effective contraception as advised by their doctor.

Breastfeeding CONSULT YOUR DOCTOR

Do not breastfeed during treatment with Monjuvi and for the recommended period after the final dose. Consult your doctor for guidance.

Driving CONSULT YOUR DOCTOR

Monjuvi may cause fatigue, dizziness, or weakness. Avoid driving if these symptoms affect your ability to drive safely.

Kidney CAUTION

Inform your doctor if you have kidney problems before starting treatment. Your doctor may recommend appropriate monitoring.

Liver CAUTION

Tell your doctor if you have liver problems. Your doctor may monitor liver function during treatment.

• Attend all scheduled Monjuvi (Tafasitamab) infusions and follow your doctor's treatment schedule carefully.
• Attend regular blood tests to monitor your blood cell counts and overall health during treatment.
• Contact your doctor promptly if you develop fever, chills, persistent cough, unusual bleeding, or other signs of infection.
• Inform your healthcare team immediately if you experience difficulty breathing, dizziness, rash, or other symptoms during or after the infusion.
• Inform your doctor about all medicines, vitamins, herbal products, and dietary supplements you are taking to help prevent possible drug interactions.
• Read More About - Monjuvi (Tafasitamab) from Pharma Five.

Pharma Five, can assist patients with the import of Monjuvi (Tafasitamab) in small quantities for personal use. The applicant is required to submit an application in Form 12A along with a prescription issued by a Registered Medical Practitioner (RMP).

With over 20 years of industry experience, Pharma Five assists patients in obtaining access to Monjuvi (Tafasitamab) and other specialized medicines through professional pharmaceutical import facilitation. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.